Headquartered in Charlotte, NC, Alveolus is an emerging leader in the development of non-vascular interventional stent technology. Alveolus' advanced stenting technology is designed to enhance the quality of life for patients who suffer from malignant pulmonary and gastrointestinal obstructive lumen diseases.

The Company, whose products are developed by physicians for physicians, has developed a next-generation stent for use in the lungs and esophagus, and is in various stages of development with stents for use in the colon, duodenum, pancreas, biliary tract and other ducts.

Alveolus has partnered itself with business leaders, thought-leading physicians, and internationally recognized medical institutions in order to build value and quality in the creation of curative and palliative treatment alternatives.